Multifunctional nanoparticles for combinational therapy of pancreatic cancer

用于胰腺癌联合治疗的多功能纳米颗粒

• 批准号: 8812549
• 负责人: Juan Luis Vivero-Escoto
• 金额: $ 43.72万
• 依托单位: UNIVERSITY OF NORTH CAROLINA CHARLOTTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-12-23 至 2018-06-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8812549
• 关键词: Acute; Antibodies; Area; Behavior; Biodistribution; Cancer Etiology; Cessation of life; Chemicals; Chronic; Clinical Research; Combined Modality Therapy; Development; Diagnosis; Disease; Drug Kinetics; Drug Targeting; Early Diagnosis; Evaluation; Glycoproteins; Goals; Grant; Human; Lead; Legal patent; Malignant neoplasm of pancreas; Medicine; Metastatic Lesion; Modeling; Modification; Monitor; Multi-Drug Resistance; Outcome; Outcomes Research; Pancreatic Ductal Adenocarcinoma; Pharmaceutical Preparations; Polymers; Pre-Clinical Model; Predictive Value; Public Health; Refractory; Research; Resistance; Silicon Dioxide; Structure; Surface; Survival Rate; Tandem Repeat Sequences; Techniques; Therapeutic; Toxic effect; Transgenic Mice; Transgenic Organisms; Treatment Efficacy; Triplet Multiple Birth; United States; Work; base; biomaterial compatibility; cancer diagnosis; cancer therapy; cancer type; chemotherapy; clinical care; clinically relevant; combinatorial; conventional therapy; dosage; drug development; gemcitabine; improved; in vivo; interest; mouse model; nanomaterials; nanomedicine; nanoparticle; next generation; novel; novel strategies; outcome forecast; prevent; public health relevance; scaffold; targeted treatment; tumor; tumorigenesis

DESCRIPTION (provided by applicant): The long term goal of this research is to develop clinically relevant multimodal MSN-based therapeutic strategies with the ability of overcoming chemo and stromal resistance to improve the final outcome of pancreatic ductal adenocarcinoma (PDAC) treatment. PDAC is the fourth leading cause of cancer death in the United States. This is one of the most difficult conditions to treat, with a 5-year survival at abot 6%. The horrific prognosis of PDAC is a result of late diagnosis and the tumor's refractory behavior toward current drug treatment. Mesoporous silica nanoparticles (MSNs) hold considerable promise as the next generation of nanomedicine that enables the early detection of disease, simultaneous monitoring and treatment, and targeted therapy with minimal toxicity. The hypothesis underlying this proposal is that by using MSNs as scaffold, we can combine different therapies such as chemotherapy, targeted therapy and combination therapy to overcome some of the main deficiencies in the current treatment of PDAC. The main target of this proposal is to develop multimodal MSN-based therapeutic strategies with the ability of overcoming chemo and stromal resistance to improve the final outcome of PDAC treatment. This goal will be accomplished by completion of three Specific Aims: 1) To develop novel MSN-based approaches for combinatorial chemotherapy and targeted therapy of PDAC; 2) To evaluate the in vivo biodistribution, pharmacokinetics, targeting ability and therapeutic efficacy of MSN materials developed in Aim 1; and 3) To develop MSN-based delivery platforms that combine chemotherapy and targeted therapy with stromal-depleting agents as novel strategies to improve PDAC treatment. The results of this work will lead to the development of several platforms with the ability of overcoming chemo and stromal resistance to improve the treatment of PDAC. Moreover; the in vivo results, obtained from a unique triplet transgenic PDAC mouse model, will provide the proof of concept to justify the evaluation of these platforms in clinical studies. These advancements in PDAC treatment will eventually impact the clinical care of this deadly disease.

描述（由申请人提供）：这项研究的长期目标是开发临床上相关的基于MSN的治疗策略，具有克服化学疗法和基质耐药性以改善胰腺导管腺癌（PDAC）治疗的最终结果的能力。 PDAC是美国癌症死亡的第四个主要原因。这是治疗最困难的条件之一，为6％的ABOT生存了5年。 PDAC的可怕预后是诊断后期诊断和肿瘤对当前药物治疗的难治行为的结果。介孔二氧化硅纳米颗粒（MSNS）具有相当大的希望，是下一代纳米医学，可以早期发现疾病，同时监测和治疗，并以最小的毒性进行靶向治疗。该提议的基本假设是，通过将MSN用作支架，我们可以结合不同的疗法，例如化学疗法，靶向疗法和联合疗法，以克服当前PDAC治疗中一些主要缺陷。该提案的主要目标是开发基于多模式的基于MSN的治疗策略，具有克服化学和基质耐药性以改善PDAC治疗的最终结果的能力。该目标将通过完成三个特定目的来实现：1）开发新型基于MSN的方法，用于组合化学疗法和PDAC的靶向疗法； 2）评估AIM 1中开发的MSN材料的体内生物分布，药代动力学，靶向能力和治疗功效； 3）开发基于MSN的输送平台，将化学疗法和靶向治疗与基质止血剂结合在一起，作为改善PDAC治疗的新型策略。这项工作的结果将导致几个平台的发展，具有克服化学疗法和基质耐药性改善PDAC处理的能力。而且;从独特的三重转基因PDAC小鼠模型获得的体内结果将提供概念验证，以证明在临床研究中对这些平台的评估是合理的。 PDAC治疗中的这些进步最终将影响这种致命疾病的临床护理。

项目成果

Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model.

• DOI: 10.1166/jbn.2016.2318
• 发表时间: 2016-12
• 期刊: Journal of biomedical nanotechnology
• 影响因子: 2.9
• 作者: Dréau D;Moore LJ;Alvarez-Berrios MP;Tarannum M;Mukherjee P;Vivero-Escoto JL
• 通讯作者: Vivero-Escoto JL

Cellular Endocytosis and Trafficking of Cholera Toxin B-Modified Mesoporous Silica Nanoparticles.

• DOI: 10.1039/c5tb02079d
• 发表时间: 2016-02-21
• 期刊: Journal of materials chemistry. B
• 作者: Walker WA;Tarannum M;Vivero-Escoto JL
• 通讯作者: Vivero-Escoto JL

Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.

• DOI: 10.1016/j.jconrel.2022.05.019
• 发表时间: 2022-05
• 期刊: Journal of controlled release : official journal of the Controlled Release Society
• 作者: M. Tarannum;Katherine Holtzman;D. Dréau;P. Mukherjee;Juan L. Vivero-Escoto

In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin.

• DOI: 10.2147/ijn.s118196
• 发表时间: 2016
• 期刊: International journal of nanomedicine
• 影响因子: 8
• 作者: Alvarez-Berríos MP;Vivero-Escoto JL
• 通讯作者: Vivero-Escoto JL

Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors.

• DOI: 10.1016/j.tranon.2016.05.001
• 发表时间: 2016-08
• 期刊: TRANSLATIONAL ONCOLOGY
• 影响因子: 5
• 作者: Moore, Laura Jeffords;Roy, Lopamudra Das;Zhou, Ru;Grover, Priyanka;Wu, Shu-ta;Curry, Jennifer M.;Dillon, Lloye M.;Puri, Priya M.;Yazdanifar, Mahboubeh;Puri, Rahul;Mukherjee, Pinku;Dreau, Didier
• 通讯作者: Dreau, Didier